Aspen is a biotechnology company developing autologous cell therapies, including the first iPSC-derived autologous neuron replacement treatment for Parkinson's disease (PD).
Aspen is developing enabling technologies for patient-specific induced pluripotent stem cell-based therapies.
Aspen Neuroscience was founded in 2018 by Jeanne Loring. The company is headquartered in La Jolla, California.
Aspen Neuroscience leverages stem cell biology and genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson disease.
Aspen’s first product is currently undergoing investigational new drug (IND)-enabling studies for the treatment of sporadic forms of Parkinson disease, the company said. Its second product uses gene correction and neuron therapy to try to treat genetic forms of Parkinson disease.
Aspen's process allows for a reduction in the time and cost of the manufacturing process required to produce a safe, reproducible, and personalized autologous cell therapy.
Aspen is backed by OrbiMed, GV, ARCH Venture Partners, Frazier Healthcare Partners, LYFE Capital, Revelation Partners, Newton Investment Management, EDBI, Domain Associates, and others. The company raised $147.5M in Series B round on May 09, 2022. This brings Aspen's total funding to $224M to date.